Literature DB >> 2675587

Usefulness of nifedipine for myocardial ischemia and the nifedipine gastrointestinal therapeutic system.

N Bittar1.   

Abstract

Although conventional treatment of angina pectoris with nifedipine capsules involves frequent daily dosing, a new vehicle for the once-daily delivery of this potent but insoluble calcium channel blocking agent has been developed. With the gastrointestinal therapeutic system (GITS) formulation, constant effective drug levels of nifedipine are delivered for a full 24-hour period. When nifedipine GITS 30, 60 or 90 mg was administered once daily to patients with stable angina pectoris taking beta blockers, clinical effectiveness was demonstrated both by an increase in time to angina and by exercise time compared with placebo. Improvement was noted to be more significant with the higher doses of nifedipine administered once daily. This study indicates that nifedipine GITS provides additional antianginal protection in patients with exercise-induced angina secondary to coronary artery disease who are receiving a fixed dose of beta blocker.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2675587     DOI: 10.1016/0002-9149(89)90743-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?

Authors:  M C Ruddy
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 2.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 3.  Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.